Faculty Perspectives: The Evolving Clinical and Pharmacoeconomic Impact of Isatuximab in Multiple Myeloma Management
For this supplement, the expert faculty provided detailed perspectives on the evolving role of isatuximab in the multiple myeloma treatment paradigm, including their point of view on recent data from the phase 3 GMMG HD7 study and the cost implications for the use of isatuximab-based regimens in myeloma, along with their overall impressions of the current costs of myeloma care and treatment.
MM is a clonal malignancy of terminally differentiated
plasma cells, characterized by the accumulation of malignant
cells in the bone marrow. Read More ›